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Angiography in a National Veterans Health Administration Cohort
With External Validation
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Mary E. Plomondon, PhD, MSPH; Christopher D. Nielson, MD, MPH; Edward D. Siew, MD, MSCI; Frederic S. Resnic, MD, MS;
Clifton R. Baker, MA; John S. Rumsfeld, MD, PhD; Michael E. Matheny, MD, MSc, MPH
Background-—Acute kidney injury (AKI) occurs frequently after cardiac catheterization and percutaneous coronary intervention.
Although a clinical risk model exists for percutaneous coronary intervention, no models exist for both procedures, nor do existing
models account for risk factors prior to the index admission. We aimed to develop such a model for use in prospective automated
surveillance programs in the Veterans Health Administration.
Methods and Results-—We collected data on all patients undergoing cardiac catheterization or percutaneous coronary intervention
in the Veterans Health Administration from January 01, 2009 to September 30, 2013, excluding patients with chronic dialysis, end-
stage renal disease, renal transplant, and missing pre- and postprocedural creatinine measurement. We used 4 AKI definitions in
model development and included risk factors from up to 1 year prior to the procedure and at presentation. We developed our
prediction models for postprocedural AKI using the least absolute shrinkage and selection operator (LASSO) and internally
validated using bootstrapping. We developed models using 115 633 angiogram procedures and externally validated using 27 905
procedures from a New England cohort. Models had cross-validated C-statistics of 0.74 (95% CI: 0.74–0.75) for AKI, 0.83 (95% CI:
0.82–0.84) for AKIN2, 0.74 (95% CI: 0.74–0.75) for contrast-induced nephropathy, and 0.89 (95% CI: 0.87–0.90) for dialysis.
Conclusions-—We developed a robust, externally validated clinical prediction model for AKI following cardiac catheterization or
percutaneous coronary intervention to automatically identify high-risk patients before and immediately after a procedure in the
Veterans Health Administration. Work is ongoing to incorporate these models into routine clinical practice. ( J Am Heart Assoc.
2015;4:e002136 doi: 10.1161/JAHA.115.002136)
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A cute kidney injury (AKI) occurs frequently after cardiaccatheterization or percutaneous coronary intervention
(PCI)1 with more than 5-fold variability in incidence across
hospitals.2 Patients developing AKI have an increased risk of
short- and long-term mortality3,4 and progression of renal
disease.5,6
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ORIGINAL RESEARCH
A number of preprocedural and periprocedural protocols
have been developed to minimize the occurrence of AKI in
these patients.2,7–9 Current risk models have been developed
largely identifying patient risk factors at the time of the
PCI10,11 and others including procedural risk factors.12–14
However, current models have not evaluated the predictive
ability of patient factors and clinical biomarkers from the year
prior to the procedure, nor with external validation. As more
healthcare systems participate in health information
exchanges, such as the integrated Veterans Administration
healthcare system, and provide increasing levels of integrated
outpatient and inpatient management to address quality
metrics and systems-based care requirements, more clinical
data are becoming available and should be considered in
prediction rules.
There are a number of postcatheterization AKI risk
prediction models published outside of the Veterans Health
Administration (VA).10,12,15–22 A national association study
was done using the American College of Cardiology’s National
Cardiovascular Data Registry (ACC-NCDR) for predicting AKI,
but these data have not yet been developed into a model and
internally validated.13 Additionally, no model for prospectively
predicting risk of AKI for patients undergoing either cardiac
catheterization or PCI in the VA has been developed for
routine clinical use. There is a growing body of literature that
supports the need for each healthcare system to perform
recalibration and remodeling on a regular basis within their
own healthcare data in order to ensure sustained high
performance for individual patient prediction. In addition, the
comprehensive nature of the VA electronic health record
(EHR) data sources allows novel risk factors to be explored
and tested for importance in risk prediction.
Therefore, we sought to develop an externally validated
national prediction model for AKI occurring after cardiac
catheterization or PCI for prospective automated surveillance.
We hypothesized that risk factors from 1 year prior to,
immediately before, and during the procedure would predict
AKI in the VA.
Methods
Study Setting and Design
We developed and internally validated a set of risk prediction
models for postprocedural AKI following cardiac catheteriza-
tion within a national VA cohort. This cohort included
222 669 catheterization procedures among 70 centers
between January 1, 2009 and October 1, 2013. The Institu-
tional Review Board approved this study with a waiver of
patient consent.
The Clinical Assessment, Reporting and Tracking Program
(CART) is a national clinical quality initiative for VA cardiac
catheterization laboratories that began in 2005 and was in
use in all of these laboratories by the beginning of 2008.23
The CART program includes a clinical software application
designed to collect standardized data on all coronary
angiograms and PCI. This software was designed to support
clinical workflow and documentation. All data elements are
mapped to the definitions and standards of the ACC-
NCDR.24,25
The VA is an integrated care network that includes acute
inpatient hospitals, outpatient primary care and subspecialty
clinics, outpatient pharmacies, rehabilitation facilities, and
long-term care facilities and domiciliaries. All VA clinical
providers and allied health personnel are required to use the
same EHR for documentation and execution of all clinical
care. The VA Central IRB and site VA R&D committees at VA
Tennessee Valley Healthcare System, VA Eastern Colorado
Healthcare System, and White River Junction, Vermont VA
approved this study.
The external validation cohort was provided by the
Northern New England Cardiovascular Disease Study Group
(NNECDSG), which includes participating medical centers in
New Hampshire, Maine, and Vermont. At total of 27 905
patients were included in the external validation cohort.
Data Collection
Data were collected from a retrospective VA cohort of adult
patients with a cardiac catheterization, with or without
intervention. All data for these patients were retrieved
beginning 1 year prior to the first cardiac catheterization in
the cohort (January 1, 2008). Each patient coronary
angiogram or PCI procedure that occurred within the same
day as cardiac catheterization was aggregated into a single
procedure for the study. The data were collected from 2
national VA sources: (1) the CART program, and (2) the EHR
data available from the Corporate Data Warehouse. The CART
program was used to identify procedures and to collect
contrast administration data. EHR data from the Corporate
Data Warehouse was used for inpatient admission and
administrative data, chemistry and hematology laboratory
data, outpatient pharmacy fill records, and inpatient bar-
coded medication administration. Both domains were merged
for patient demographics.
Data Definitions
A complete description of data definitions is included in Data
S1. Estimated glomerular filtration rates were calculated for
all serum creatinine measures using the readily available
abbreviated Modification of Diet and Renal Disease equation.
Chronic kidney disease was defined as a baseline estimated
glomerular filtration rate <60 mL/min per 1.73 m2.26,27
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Chronic comorbidities were defined using administrative
Current Procedural Terminology and International Statistical
Classification of Diseases, 9th Revision (ICD-9) diagnostic
codes collected from data prior to hospital admission.
Substantial ICD-9 validation work has been performed
previously in the Veterans Affairs and in general popula-
tions.28,29 Additional related ICD-9 codes used were aimed at
increasing sensitivity to these validated codes.
Cohort Inclusion and Exclusion Criteria
Procedures were included if they had at least 1 serum
creatinine measurement within 1 day to 365 days prior to
cardiac catheterization and at least 1 serum creatinine
measurement from 0 to 7 days following the procedure.
Procedures were excluded if they had a renal transplant, or if
they had end-stage renal disease, which is defined as
requiring chronic dialysis or having a baseline estimated
glomerular filtration rate of <15 mL/min per 1.73 m2
(n=6998) at the time of the procedure. Procedures with
missing pre- (21 014) or postprocedure serum creatinine
(79 024) were excluded, which left a total of 115 633 patient
procedures (Figure 1). A comparison of procedures included
in the cohort with procedures excluded due to missing serum
creatinine is reported in Table S1.
Outcome Definitions
AKI was defined using the Kidney Disease Improving Global
Outcomes Guidelines definition: ≥0.3 mg/dL within 48 hours
of the procedure or ≥50% increase in serum creatinine from
baseline to the post–cardiac catheterization peak serum
creatinine at any time during the hospitalization or up to
7 days following the procedure.30 Baseline creatinine was
defined as the most recent serum creatinine between 365 and
7 days prior to the procedure, which is a method previously
validated in the literature.31 Acute Kidney Injury Network
Stage 2 (AKIN2) was defined as a doubling in serum creatinine
from baseline or developing new dialysis-dependent renal
failure. Contrast-induced nephropathy (CIN) was defined by
≥0.5 mg/dL within 7 days following the procedure. Dialysis
was identified by any new dialysis-dependent renal failure
within 7 days following the procedure. The timing of the post–
cardiac catheterization creatinine values is +1 to +7 days with
mean of 2 days and a SD of 5 days.
Statistical Analysis
Procedures with incomplete pre- and postprocedure serum
creatinine were excluded from the analysis. Dichotomous
variables reflecting the presence of medical conditions were
set to zero if they were coded as missing (eg, absent). Dummy
variables were created for variables with greater proportions
of missing values (eg, intravenous fluids and laboratory
values) and modeled against dummy categories (eg, missing
values dummy modeled against known intravenous fluid
status prior to the procedure dummy variables). Predicted
values were imputed for missing contrast volume using case
complexity, number of vessels receiving direct intervention,
and number of stents deployed. We developed prediction
rules using logistic regression with variable selection by using
the least absolute shrinkage and selection operator (LASSO).
LASSO obtains coefficient estimates by maximizing a likeli-
hood with a L1 penalty on coefficient size, for a sequence of
penalty parameters.32 LASSO has the property that only a
subset of variables in the model will have nonzero coeffi-
cients, which makes it a variable selection tool. We report the
LASSO models for which the penalty term resulted in a
maximized cross-validated likelihood. The predictive ability of
the model is reported using the C-statistic (area under the
Receiver Operating Characteristic (ROC) curve, AUC) cor-
rected for overfitting using bootstrap validation by sampling
the dataset with 200 iterations, and by plotting calibration of
the model using (observed versus predicted rates of AKI after
binning of predicted values). The bootstrap distribution of C-
statistic values was used to obtain 95% CIs around the AUC.
Sensitivity analyses were conducted re-running the models
based on a 48-hour definition of AKI end points and again on
unique patients. We considered all pairwise interactions, but
excluded all from the model because none increased the C-
statistic by more than 0.001. Analyses were conducted using
R (library glmnet (http://cran.r-project.org/web/packages/
glmnet/glmnet.pdf) and Stata.
External validation was conducted as follows: First, as the
NNE cohort does not collect EHR variables from preceding
outpatient encounters, each of the 4 models was reduced to
only include variables also available in the NNE external
validation cohort. Second, LASSO was performed again on the
common variables of the VA and NNE cohorts. Third, the model
development and bootstrapping methods were repeated in the
VA cohort for the reduced VA models. Last, the coefficients from
the VA reduced models were then used to calculate the NNE
external validation ROC and 95% CI for each of the 4 models.
Figure 1. Study flow diagram. Summary of the inclusion and
exclusion criteria for the procedure-based cohort. ESRD indicates
end-stage renal disease.
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Table 1 shows the characteristics of the cohort for the AKI
and non-AKI groups, including demographics, prior comorbid
events, comorbidities at presentation, and procedural
aspects. The univariate association (odds ratio) of each
characteristic with AKI occurrence is also presented in
Table 1. Out of a total of 115 633 coronary angiography
procedures, AKI developed in 16 036 (13.9%), while the
number with AKIN Stage 2 was 2017 (1.7%), the number with
CIN was 13 763 (14.4%), and 476 (0.4%) received dialysis
treatment for AKI.
Using the variables included in Table 1, we built a logistic
regression model for prediction of AKI occurrence using
LASSO. Table 2 contains the odds ratios we obtained from
fitting this model to our data. First from the left is the
LASSO-derived model for patients developing AKI. The
overfitting-corrected C-statistic for the AKI prediction model
was 0.742 (95% CI: 0.738–0.747). The second column
contains the LASSO-derived model results for patients
developing AKIN Stage 2, for which the bias-corrected
C-statistic was 0.826 (95% CI: 0.816–0.836). The third
column contains our results from the model for patients
developing ≥0.5 (mg/dL) increase in serum creatinine (CIN),
with a bias-corrected C-statistic of 0.741 (95% CI: 0.737–
0.746). The last column shows the results from our LASSO-
derived model for dialysis with a bias-corrected C-statistic of
0.885 (95% CI: 0.870–0.902). We present observed-versus-
expected plots showing calibration for each model in
Figure 2. Each plot indicates strong agreement between
the observed and predicted values, although for all 4
outcomes the observed odds are below our predictions for
subjects with the lowest expected odds. We conducted
sensitivity analyses for AKI at 48 hours and by limiting the
cohort to unique patient procedures as opposed to a unique
procedure analysis. All ROCs were robust for AKI, AKIN2,
CIN, and dialysis end points: 0.768, 0.855, 0.736, and
0.895, respectively. When limiting to unique patients
(n=90 105), the ROCs for AKI, AKIN2, CIN, and dialysis
end points were 0.738, 0.826, 0.739, and 0.883, respec-
tively. Both sensitivity analyses proved the model to perform
well on a 48-hour definition for AKI end points and
restricting to unique patient procedures.
A small number of candidate variables were statistically
significant and associated consistently with occurrence of AKI
for each of our outcome definitions (Table 2). History of
diabetes was a risk factor, while prior coronary artery bypass
grafting and PCI were protective. Prior instances of congestive
heart failure and low albumin were also risk factors, as were
prior AKI by Kidney Disease Improving Global Outcomes
definition and chronic kidney disease by observed estimated
glomerular filtration rates (creatinine). Exposure to either
N-acetylcysteine, angiotensin receptor blockers, or hydrox-
ymethyl glutaryl coenzyme A reductase inhibitors at presen-
tation was protective, whereas exposure to loop diuretics was
a risk factor. Clinical presentation risk factors were catheter-
ization urgency status, shock, acute coronary syndrome, and
anemia.
External validation limited to variables included in the
NNECDSG registry showed results consistent with our VA AKI
population findings (Table 3). The final VA reduced multivari-
ate model results are shown in Table 4. The VA reduced
models performed with high agreement in ROC statistics for
all prediction end points, including any AKI occurrence (VA:
0.70, 95% CI 0.70, 0.71; NNECDSG: 0.69, 95% CI 0.68, 0.71),
CIN (VA: 0.68, 95% CI 0.68, 0.69; NNECDSG: 0.72; 95% CI
0.70, 0.74), AKIN Stage 2 (VA: 0.80, 95% CI 0.79, 0.81;
NNECDSG: 0.76, 95% CI 0.73, 0.79), and dialysis (VA: 0.85,
95% CI 0.82, 0.87; NNECDSG: 0.86, 95% CI 0.76, 0.96).
Discussion
We developed a comprehensive and externally validated
clinical prediction rule for AKI among cardiac catheterization
and/or PCI procedures in the VA. This is the first such tool
developed from national VA CART and EHR data, which
explores novel outpatient and periprocedural risk factors for
AKI. All of the models developed for different severities of
AKI had good discrimination performance (0.741–0.885),
and maintained adequate calibration across the full spec-
trum of risk in each model. Reduced VA models using
routine NCDR variables and paired with the external
validation cohort demonstrated the generalizability of our
AKI and dialysis prediction tool to non-VA catheterization
laboratories.
There are a number of risk prediction models for AKI
following PCI, but most were developed from data prior to
2005 with a variety of outcome definitions.34 The 2 most
modern coronary angiography AKI models were developed by
Tsai et al and Gurm et al. Both focused only on preprocedural
risk estimation with a wider array of candidate variables than
previously evaluated, including preprocedural inpatient med-
ication exposures, clinical history and demographics, patient
presentation characteristics, and laboratory assess-
ments.11,13
This study extends prior research by exploring additional
risk factors available within a comprehensive EHR for use
within AKI risk prediction models. Only 1 study developed a
model using both coronary angiography and PCI procedures
from 1218 patients at a single center and did not find a
multivariate association between intervention status and
AKI.35 No prior modeling study has incorporated inpatient
bar-coded records of intravenous fluid administration, which
have been shown in numerous studies to be protective of
DOI: 10.1161/JAHA.115.002136 Journal of the American Heart Association 4















Table 1. Patient and Procedural Characteristics
No AKI AKI OR (95% CI) P Value
Procedures (n=115 633) 99 596 16 037
Comorbidities
Age 65.29.5 67.210.0 1.02 (1.02–1.02) <0.001
Female 2.2 2.1 0.93 (0.83–1.05) 0.233
Nonwhite race 22.8 26.7 1.23 (1.19–1.28) <0.001
Tobacco use (any) 38.7 34.1 0.82 (0.79–0.85) <0.001
Prior tobacco use 52.7 47.5 0.81 (0.79–0.84) <0.001
Prior comorbidities
Prior catheterization 43.9 24.3 0.41 (0.40–0.43) <0.001
0 to 1 days from catheterization 33.4 19.1 0.47 (0.45–0.49) <0.001
0 to 2 days from catheterization 34.2 19.9 0.48 (0.46–0.50) <0.001
Days from catheterization 15.587.5 12.877.4 1.00 (1.00–1.00) 0.064
Prior PCI 33.5 25.5 0.68 (0.66–0.71) <0.001
Prior CABG 12.9 11.1 0.85 (0.80–0.89) <0.001
Prior MI 28.1 30.2 1.11 (1.07–1.15) <0.001
Prior stroke 7.9 8.5 1.08 (1.02–1.14) 0.014
Diabetes 48.5 51.8 1.14 (1.10–1.18) <0.001
Dyslipidemia 74.4 65.9 0.66 (0.64–0.69) <0.001
Hypertension 78.6 76.2 0.87 (0.84–0.91) <0.001
Hypotension 8.8 11.3 1.33 (1.26–1.40) <0.001
Mitral regurgitation 0.5 0.5 0.99 (0.77–1.26) 0.911
Peripheral vascular disease 19.2 22.8 1.24 (1.19–1.29) <0.001
Number of prior comorbid events
Number of prior admissions 0.71.2 0.91.6 1.12 (1.11–1.14) <0.001
CHF 0.020.14 0.020.14 1.06 (0.95–1.20) 0.286
CHF 7 to 365 days 24.1 35.8 1.76 (1.70–1.82) <0.001
CKD 0.41.9 1.13.3 1.11 (1.10–1.11) <0.001
Diabetes 4.17.7 5.19.1 1.01 (1.01–1.02) <0.001
Dyslipidemia 2.63.0 2.43.1 0.97 (0.97–0.98) <0.001
Hypertension 4.15.6 4.56.4 1.01 (1.01–1.02) <0.001
Hypoalbuminemia 7 to 30 days 5.5 13.9 2.77 (2.62–2.91) <0.001
Hypoalbuminemia 7 to 90 days 9.6 19.91 2.34 (2.24–2.45) <0.001
Hypotension 0.10.8 0.20.9 1.07 (1.05–1.09) <0.001
Peripheral vascular disease 0.82.9 1.03.4 1.02 (1.02–1.03) <0.001
Anemia 3-days 32.6 52.6 2.29 (2.22–2.37) <0.001
Anemia 3 to 90 days 33.1 46.5 1.76 (1.71–1.82) <0.001
Anemia 3 to 365 days 46.4 58.6 1.64 (1.58–1.69) <0.001
Shock events 0.00070.0454 0.00430.0943 2.22 (1.70–2.90) <0.001
CHF events 0.31.0 0.61.5 1.23 (1.21–1.24) <0.001
CKD events 0.050.37 0.130.63 1.37 (1.33–1.41) <0.001
Dyslipidemia events 0.250.66 0.210.64 0.90 (0.87–0.92) <0.001
Continued
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No AKI AKI OR (95% CI) P Value
Prior renal complications and function
Prior CKD 13.1 24.4 2.14 (2.05–2.23) <0.001
Prior AKI (KDIGO) 11.0 29.8 3.45 (3.32–3.59) <0.001
Prior highest AKIN Stage 1.83 (1.78–1.87) <0.001
AKIN Stage 1 17.9 27.4
AKIN Stage 2 2.5 7.7
AKIN Stage 3 0.6 1.7
Prior CIN (>0.5) 15.2 30.1 2.41 (2.32–2.50) <0.001
Prior ARF (ICD9) 6.5 15.5 2.64 (2.52–2.78) <0.001
Number of prior AKI admissions 0.00030.0164 0.00060.0249 2.35 (1.15–4.79) 0.019
Number of prior CKD admissions 0.00250.0547 0.00820.1097 2.48 (2.05–3.02) <0.001
Change in eGFR prior year 0.913.7 1.317.4 1.00 (1.00–1.00) 0.001
Decline in eGFR prior year 3.58.2 3.811.5 0.99 (0.99–0.99) <0.001
CKD 6.9 13.4 2.07 (1.96–2.18) <0.001
eGFR <60, mL/min per m2 14.8 33.5 2.90 (2.79–3.01) <0.001
eGFR <45, mL/min per m2 5.0 18.1 4.17 (3.96–4.38) <0.001
eGFR <30, mL/min per m2 0.9 6.7 8.14 (7.43–8.92) <0.001
Medications
ARB 9.56 9.6 1 (0.95–1.06) 0.893
ACE 41.78 38.9 0.888 (0.86–0.92) <0.001
Loop diuretic 18.99 28.4 1.69 (1.63–1.76) <0.001
K-sparing diuretic 5.77 7.7 1.37 (1.29–1.46) <0.001
Statins 62.03 54.2 0.72 (0.70–0.75) <0.001
Aminoglycosides 0.1 0.1 0.79 (0.47–1.34) 0.387
Cimetidine 0.1 0.1 0.47 (0.24–0.93) 0.031
Cyclosporine 0.3 0.4 1.46 (1.11–1.90) 0.006
N-acetylcysteine 2.6 1.7 0.67 (0.59–0.75) <0.001
NSAIDS 11.2 7.8 0.67 (0.63–0.71) <0.001
Trimethoprim 0.9 1.1 1.21 (1.03–1.42) 0.024
Thrombolytic use 0.03 0.02 0.89 (0.31–2.53) 0.823
At presentation
Hypertension 43.6 45.7 1.09 (1.05–1.12) <0.001
Hypotension 22.2 32.4 1.68 (1.62–1.75) <0.001
Prepresent MI 15.1 17.9 1.23 (1.18–1.28) <0.001
Acute coronary syndrome 23.9 32.1 1.51 (1.46–1.56) <0.001
Anemia 32.6 52.6 2.29 (2.22–2.37) <0.001
Shock 0.4 4.3 10.22 (9.06–11.55) <0.001
CHF 0.4 4.3 10.23 (9.06–11.55) <0.001
Dyslipidemia 34.2 29.6 0.81 (0.78–0.84) <0.001
Unstable angina 9.2 4.1 0.42 (0.39–0.46) <0.001
Ejection fraction ≤40% 4.05 5.58 1.40 (1.30–1.51) <0.001
Pre creatine-kinase ≥100 6.9 7.7 1.11 (1.05–1.19) 0.001
Continued
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No AKI AKI OR (95% CI) P Value
Pre CKMB ≥2.66 4.2 6.1 1.49 (1.38–1.60) <0.001
Preprocedural volume supplementation
Pre IV normal saline, mL 95.3373.9 100.2386.1 1.00 (1.00–1.00) 0.177
Pre IV total fluids, mL 176.0593.2 176.1560.3 1.00 (1.00–1.00) 0.983
Pre IV category
Missing IV fluids 21.5 20.5 0.94 (0.90–0.98) 0.005
No IV fluids 64.5 65.3 1.03 (1.00–1.07) 0.059
1 to 999 (mL) IV fluids 6.4 6.6 1.04 (0.97–1.11) 0.267
1000+ (mL) IV fluids 7.6 7.6 1.00 (0.94–1.06) 0.946
Procedural characteristics
Priority
Elective 62.7 47.6 0.55 (0.53–0.57) <0.001
Urgent 33.5 42.6 1.46 (1.41–1.51) <0.001
Emergent 3.7 9.4 2.65 (2.49–2.83) <0.001
Salvage 0.1 0.4 8.73 (6.07–12.55) <0.001
Diagnostic cardiac catheterization 86.1 92.3 1.94 (1.82–2.06) <0.001
Percutaneous coronary intervention 45.7 25.6 0.41 (0.39–0.42) <0.001
Ad hoc PCI 31.8 17.9 0.47 (0.45–0.49) <0.001
Multivessel disease 4.4 3.3 0.75 (0.68–0.82) <0.001












Stent procedure 38.6 20.4 0.41 (0.39–0.42) <0.001
Number of interventions 1.72.6 1.02.3 0.88 (0.87–0.89) <0.001
Number of stents 0.60.9 0.40.9 0.69 (0.67–0.71) <0.001
Intra-aortic balloon pump 0.8 5.7 7.21 (6.56–7.93) <0.001
Contrast type
Hexabrix 0.4 0.9 2.59 (2.14–3.13) <0.001
Isovue 15.1 11.1 0.70 (0.67–0.74) <0.001
Omnipaque 8.0 6.8 0.84 (0.79–0.90) <0.001
Other contrast 2.1 1.9 0.88 (0.78–0.99) 0.037
Ultravist 5.0 5.1 1.02 (0.95–1.10) 0.553
Unknown contrast 31.3 32.9 1.08 (1.04–1.11) <0.001
Continued
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postprocedural AKI. No prior study has included prevalent use
of outpatient medications, such nonsteroidal anti-inflamma-
tory drugs, angiotensin-converting enzyme inhibitors, angio-
tensin receptor blockers, or diuretics, all of which have been
shown to be associated with AKI.
In this study, risk factors at the time of presentation as well
as renal function or prior renal events were key variables for
predicting AKI and dialysis. Within these categories, the
strongest risk factors included urgency of the procedure,
shock, chronic kidney disease stage, and development of AKI
prior to the procedure.
We previously developed a single-center risk model to
predict hospital-acquired AKI for use in an EHR; this effort
extends that model to coronary angiography within a
national VA cohort for use in the VA EHR.36 Because we
intend these models to be used in a clinical setting, the
potential predictors are limited to those available in real-
time from the EHR and the CART clinical applications.
However, because these models provide an automated way
to predict AKI risk, they allow clinicians to account for a
larger number of variables while reducing data entry time.
Integration of these models into EHRs has not yet been met
with wide acceptance and success for several reasons. First,
they have not yet been consistently and completely adapted
for clinical practice. Second, it is difficult to update the
models regularly for maintenance of calibration. Third, we
need to expand our capacity to automate data collection in
real time, and last, we need better ways to visualize the
clinical decision process.37 The CART program and the
Office of Analytics and Business Intelligence have prioritized
the implementation of a real-time high risk AKI clinical
reminder using these models to be delivered during
preprocedural assessment.
Since the development of the Mehran CIN risk score,12
new investigations have led to the creation of new CIN and
AKI risk models with variable AKI definitions and levels of
discrimination.10,11,13,14 A recent study by the NCDR Cath-PCI
registry including 954 729 PCI patients examined the asso-
ciation of common AKI risk factors known at presentation, in
addition to contrast use and length of hospitalization.13 Unlike
the NCDR investigators, who did not focus on the develop-
ment of a risk model, the Blue Cross Blue Shield of Michigan
Cardiovascular Consortium constructed a model for CIN
(≥0.5 mg/dL increase in serum creatinine from baseline to
hospital discharge) using 48 001 PCI patients and found an
ROC of 0.85 in the study cohort and an ROC of 0.84 in the
20 572-patient internal validation cohort.11 Similarly to the
NCDR study, the Blue Cross Blue Shield of Michigan
Cardiovascular Consortium model incorporated common AKI
risk factors at presentation, including patient characteristics
(age, weight, height, and heart failure), coronary disease, PCI
indication, and priority.11,13
Nevertheless, all of these modeling approaches have been
limited only to PCI patients and have broadly excluded
diagnostic cardiac catheterization patients. In addition, past
studies have limited the definition of AKI or CIN to in-hospital
serum creatinine measurement alone, which falls short of
meeting the current Kidney Disease Improving Global
Outcomes guidelines for defining AKI.30 Our models advance
the state of AKI clinical risk modeling in several ways. First,
we include both cardiac catheterizations and PCI procedures.
Second, we use a sample of consecutive patients in a large,
national set of VA catheterization laboratories. Third, we
investigate novel risk factors by leveraging a robust
electronic medical record rich in clinical patient character-
istics including both outpatient and perioperative factors not
available in the NCDR or Blue Cross Blue Shield of Michigan
Cardiovascular Consortium clinical registries. Fourth, we
used LASSO to aid in variable selection in place of the
conventional stepwise regression approach. Fifth, implemen-
tation of our model in electronic medical recordkeeping
would eliminate the need for data entry at the time of use
and reduces the need for model parsimony. Sixth, we used a
cross-validated model fit selection to eliminate overfitting.
Seventh, we incorporated the new Kidney Disease Outcomes
Quality Initiative AKI guidelines to include serum creatinine
measures up to 7 days postprocedure from inpatient or
outpatient blood draws.30
Table 1. Continued
No AKI AKI OR (95% CI) P Value
Visipaque270 5.5 6.3 1.16 (1.08–1.24) <0.001
Visipaque320 24.4 23.0 0.93 (0.89–0.97) <0.001
Contrast volume, mL 155.2104.1 125.8103.4 1.00 (1.00–1.00) <0.001
Contrast: GFR ratio33 2.11.7 2.12.5 1.01 (1.00–1.02) 0.013
Contrast GFR ratio >3 12.5 14.9 1.22 (1.16–1.28) <0.001
ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ARB, angiotensin receptor blockers; ARF, acute renal failure; CABG, coronary
artery bypass grafting; CHF, congestive heart failure; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; CKMB, creatinine kinase, muscle and brain subunits; eGFR,
estimated glomerular filtration rate; ICD9, Current Procedural Terminology and International Statistical Classification of Diseases, 9th Revision; IV, intravenous; KDIGO, kidney disease
improving global outcomes; MI, myocardial infarction; NSAIDS, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PCI, percutaneous coronary intervention.
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Table 2. Multivariable Logistic Regression Models for Predicting AKI, AKIN Stage 2, CIN, and Dialysis Selected Using LASSO With
Maximumized Cross-Validation
Risk Factor
AKI AKIN 2 CIN Dialysis
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Comorbidities
Age 1.01 (1.01–1.01)* 1.00 (1.00–1.00) 1.00 (1.00–1.00) 1.00 (1.00–1.00)
Nonwhite race 1.10 (1.06–1.15)* 1.14 (1.09–1.18)* 1.01 (0.98–1.05) 1.26 (1.22–1.30)*
Tobacco use (any) 0.90 (0.86–0.95)* 0.92 (0.88–0.97)* 0.98 (0.93–1.03) 0.82 (0.79–0.86)*
Prior tobacco use 0.99 (0.94–1.04) 1.00 (0.95–1.05) 1.00 (0.95–1.05) 1.00 (0.96–1.04)
Prior comorbidities
0 to 1 days from catheterization 0.60 (0.50–0.72)* 0.87 (0.74–1.03) 0.89 (0.77–1.03) 0.70 (0.61–0.81)*
0 to 2 days from catheterization 0.88 (0.73–1.05) 0.90 (0.76–1.05) 0.61 (0.53–0.71)* 1.00 (0.87–1.15)
Prior PCI 0.79 (0.76–0.82)* 0.79 (0.76–0.82)* 0.83 (0.80–0.86)* 0.89 (0.87–0.92)*
Prior CABG 0.82 (0.77–0.86)* 0.87 (0.83–0.92)* 0.86 (0.82–0.90)* 0.84 (0.80–0.88)*
Prior MI 1.00 (0.95–1.06) 0.97 (0.92–1.02) 1.00 (0.95–1.05) 1.00 (0.96–1.05)
Prior stroke 1.06 (1.00–1.13) 0.88 (0.83–0.93)* 1.02 (0.96–1.08) 0.93 (0.88–0.98)*
Diabetes 1.10 (1.06–1.15)* 1.30 (1.25–1.36)* 1.25 (1.20–1.29)* 1.35 (1.30–1.39)*
Dyslipidemia 0.78 (0.74–0.82)* 0.95 (0.91–1.00)* 0.87 (0.83–0.91)* 0.73 (0.70–0.75)*
Hypertension 0.90 (0.86–0.94)* 1.21 (1.15–1.26)* 1.04 (0.99–1.08) 0.91 (0.88–0.95)*
Hypotension 0.96 (0.89–1.04) 0.99 (0.92–1.07) 0.88 (0.83–0.94)* 1.00 (0.94–1.07)
Mitral regurgitation 0.89 (0.71–1.12) 0.81 (0.65–1.01) 1.03 (0.83–1.28) 0.34 (0.29–0.41)*
Peripheral vascular disease 1.09 (1.03–1.15)* 1.11 (1.06–1.17)* 1.00 (0.95–1.05) 1.00 (0.96–1.04)
Number of prior comorbid events
Number of prior admissions 0.98 (0.96–1.00)* 0.98 (0.96–1.00)* 1.00 (0.99–1.02) 0.95 (0.93–0.96)*
CHF 1.17 (1.04–1.33)* 1.14 (1.02–1.29)* 1.04 (0.94–1.16) 0.85 (0.78–0.93)*
CHF 7 to 365 days 1.13 (1.07–1.18)* 1.23 (1.17–1.29)* 1.08 (1.04–1.13)* 1.08 (1.04–1.12)*
CKD 1.00 (0.99–1.02) 1.00 (0.98–1.02) 0.99 (0.98–1.01) 1.04 (1.02–1.07)*
Diabetes 1.00 (1.00–1.01)* 1.00 (1.00–1.00) 1.00 (1.00–1.01) 1.00 (1.00–1.00)
Dyslipidemia 1.00 (0.99–1.01) 0.99 (0.98–0.99)* 0.99 (0.98–1.00)* 1.00 (0.99–1.01)
Hypertension 0.99 (0.99–1.00)* 1.00 (0.99–1.00) 1.00 (1.00–1.00) 0.99 (0.98–0.99)*
Hypoalbuminemia 7 to 30 days 1.26 (1.10–1.44)* 1.09 (0.95–1.25) 1.19 (1.06–1.33)* 1.19 (1.07–1.31)*
Hypoalbuminemia 7 to 90 days 1.05 (0.95–1.15) 1.33 (1.20–1.47)* 1.14 (1.05–1.24)* 1.00 (0.93–1.08)
Hypotension 0.97 (0.95–1.00) 0.99 (0.96–1.02) 0.98 (0.96–1.01) 0.96 (0.93–0.98)*
Peripheral vascular disease 1.00 (0.99–1.01) 1.00 (0.99–1.01) 1.00 (1.00–1.01) 1.02 (1.01–1.02)*
Shock events 0.66 (0.37–1.16) 0.65 (0.37–1.15) 0.55 (0.31–0.95)* 0.76 (0.47–1.24)
CHF Events 1.06 (1.03–1.09)* 1.03 (1.00–1.05)* 1.09 (1.07–1.12)* 1.00 (0.98–1.02)
CKD events 0.95 (0.88–1.04) 0.94 (0.87–1.02) 0.92 (0.87–0.97)* 0.93 (0.86–1.01)
Dyslipidemia events 0.96 (0.93–0.99)* 1.00 (0.97–1.03) 0.98 (0.95–1.01) 1.00 (0.98–1.02)
Prior renal complications and function
Prior CKD 1.09 (1.01–1.18)* 1.00 (0.93–1.08) 0.83 (0.79–0.89)* 1.73 (1.60–1.87)*
Prior AKI (KDIGO) 1.88 (1.73–2.04)* 1.72 (1.59–1.86)* 1.58 (1.48–1.68)* 1.44 (1.36–1.53)*
Prior highest AKIN Stage 1.14 (1.08–1.21)* 1.24 (1.17–1.31)* 1.00 (0.96–1.05) 1.35 (1.29–1.41)*
Prior CIN (>0.5) 1.07 (0.99–1.15) 1.13 (1.05–1.21)* 1.35 (1.27–1.44)* 0.88 (0.83–0.94)*
Prior ARF (ICD9) 1.04 (0.94–1.16) 1.02 (0.93–1.13) 0.99 (0.91–1.07) 1.11 (1.03–1.21)*
Number of prior AKI admissions 0.68 (0.13–3.48) 1.00 (0.10–9.78) 0.94 (0.23–3.88) 1.58 (0.07–36.35)
Number prior CKD admissions 1.10 (0.70–1.70) 1.28 (0.72–2.26) 0.93 (0.69–1.25) 1.41 (0.77–2.57)
Continued
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AKI AKIN 2 CIN Dialysis
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Change in eGFR prior year 1.00 (1.00–1.00)* 0.99 (0.99–1.00)* 0.98 (0.98–0.98)* 1.00 (1.00–1.00)
Decline in eGFR prior year 1.01 (1.00–1.01)* 1.01 (1.01–1.02)* 1.01 (1.00–1.01)* 1.00 (1.00–1.00)
CKD 1.13 (1.02–1.25)* 1.00 (0.91–1.10) 0.91 (0.84–0.99)* 1.34 (1.22–1.46)*
eGFR <60, mL/min per m2 1.37 (1.28–1.47)* 1.50 (1.41–1.60)* 1.28 (1.21–1.35)* 1.19 (1.14–1.25)*
eGFR <45, mL/min per m2 1.31 (1.14–1.52)* 1.37 (1.20–1.56)* 1.40 (1.27–1.55)* 2.02 (1.80–2.27)*
eGFR <30, mL/min per m2 2.06 (1.29–3.27)* 3.81 (1.82–8.00)* 2.74 (2.06–3.64)* 5.52 (1.76–17.29)*
Presenting medication use
ARB 0.94 (0.88–0.99)* 0.93 (0.88–0.98)* 0.93 (0.88–0.98)* 0.89 (0.85–0.94)*
ACE 0.99 (0.95–1.03) 1.00 (0.97–1.04) 1.00 (0.97–1.03) 0.85 (0.82–0.87)*
Loop diuretic 1.08 (1.03–1.14)* 1.15 (1.09–1.21)* 1.08 (1.03–1.13)* 1.38 (1.32–1.44)*
K-sparing diuretic 1.02 (0.94–1.10) 1.00 (0.93–1.08) 0.97 (0.91–1.04) 0.79 (0.74–0.84)*
Statins 0.87 (0.84–0.91)* 0.83 (0.80–0.86)* 0.86 (0.84–0.90)* 0.76 (0.74–0.79)*
Aminoglycosides 0.73 (0.47–1.12) 1.00 (0.64–1.57) 1.00 (0.65–1.54) 0.89 (0.62–1.28)
Cimetidine 0.64 (0.43–0.94)* 0.55 (0.39–0.77)* 1.00 (0.65–1.53) 0.78 (0.56–1.09)
Cyclosporine 1.00 (0.72–1.40) 1.00 (0.71–1.40) 1.00 (0.74–1.36) 1.22 (0.87–1.70)
N-acetylcysteine 0.80 (0.73–0.88)* 0.78 (0.72–0.85)* 0.74 (0.68–0.81)* 0.84 (0.77–0.91)*
NSAIDS 0.87 (0.83–0.91)* 1.00 (0.96–1.05) 0.93 (0.89–0.98)* 0.96 (0.93–1.00)*
Trimethoprim 0.88 (0.73–1.05) 1.00 (0.83–1.21) 1.00 (0.83–1.21) 1.00 (0.86–1.17)
Thrombolytic 0.94 (0.34–2.58) 1.00 (0.33–3.02) 1.00 (0.40–2.51) 1.00 (0.46–2.17)
Clinical presentation
Elective 0.87 (0.79–0.95)* 0.60 (0.55–0.65)* 0.87 (0.80–0.94)* 0.82 (0.76–0.87)*
Urgent 1.21 (1.10–1.33)* 1.00 (0.91–1.10) 1.16 (1.06–1.26)* 1.00 (0.93–1.08)
Emergent 2.72 (2.32–3.18)* 3.54 (2.96–4.24)* 2.97 (2.59–3.40)* 2.46 (2.19–2.75)*
Salvage 4.87 (0.92–25.76) 8.05 (0.34–191.31) 4.16 (1.47–11.83)* 1.78 (0.83–3.84)
Unstable angina 0.73 (0.70–0.77)* 0.61 (0.58–0.63)* 0.76 (0.73–0.80)* 1.00 (0.96–1.04)
Shock 4.46 (2.30–8.67)* 4.76 (1.99–11.39)* 4.76 (2.97–7.65)* 4.14 (2.69–6.40)*
Hypertension 0.94 (0.91–0.98)* 0.86 (0.83–0.89)* 0.96 (0.93–1.00)* 0.96 (0.94–0.99)*
Hypotension 1.04 (0.99–1.08) 1.30 (1.24–1.35)* 1.16 (1.11–1.20)* 1.00 (0.97–1.04)
Ejection fraction ≤40% 1.13 (1.03–1.24)* 0.96 (0.88–1.04) 1.12 (1.03–1.21)* 1.00 (0.93–1.07)
Acute coronary syndrome 1.33 (1.26–1.39)* 1.13 (1.08–1.18)* 1.24 (1.19–1.29)* 1.08 (1.04–1.12)*
Pre-creatine-kinase ≥100 0.88 (0.82–0.95)* 1.00 (0.93–1.07) 0.94 (0.88–1.00) 1.00 (0.94–1.06)
Pre CKMB ≥2.66 1.18 (1.06–1.31)* 1.00 (0.91–1.10) 1.13 (1.04–1.24)* 1.00 (0.93–1.08)
Prepresent MI 1.06 (0.99–1.13) 1.10 (1.03–1.18)* 1.06 (1.00–1.13) 1.04 (0.99–1.10)
Dyslipidemia 0.96 (0.92–1.01) 0.98 (0.94–1.03) 1.00 (0.96–1.05) 0.81 (0.79–0.84)*
Anemia 1.30 (1.25–1.36)* 1.23 (1.18–1.27)* 1.28 (1.23–1.32)* 1.16 (1.12–1.19)*
Preprocedural volume supplementation
No IV fluids 1.02 (0.98–1.06) 1.00 (0.96–1.04) 1.00 (0.96–1.04) 0.96 (0.93–0.99)*
1 to 999 (mL) IV fluids 1.02 (0.95–1.09) 1.00 (0.94–1.07) 1.00 (0.94–1.07) 1.00 (0.94–1.06)
1000+ (mL) IV fluids 1.02 (0.96–1.09) 0.99 (0.93–1.06) 1.02 (0.96–1.09) 1.00 (0.95–1.05)
ACE indicates angiotensin-converting enzyme; AKI, acute kidney injury; AKIN, acute kidney injury network; ARB, angiotensin receptor blockers; ARF, acute renal failure; CABG, coronary
artery bypass grafting; CHF, congestive heart failure; CIN, contrast-induced nephropathy; CKD, chronic kidney disease; CKMB, creatinine kinase, muscle and brain subunits; eGFR,
estimated glomerular filtration rate; ICD9, Current Procedural Terminology and International Statistical Classification of Diseases, 9th Revision; IV, intravenous; KDIGO, kidney disease
improving global outcomes; LASSO, least absolute shrinkage and selection operator; MI, myocardial infarction; NSAIDS, nonsteroidal anti-inflammatory drugs; OR, odds ratio; PCI,
percutaneous coronary intervention.
*P<0.05.
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We developed our prediction model based on a sample of VA
users, in which females are under-represented and low-
income and complex patients are over-represented. Because
some patients receive some of their care outside of the VA
system, we might have been unable to identify all prior events.
Despite searching multiple data sets in the VA, postprocedure
serum creatinine was missing for a large proportion of the
population. However, this issue is common across all cardiac
catheterization populations for coronary angiography because
patients are released the same day of the procedure without
creatinine measurement follow-up. Even though we need to
account for this limitation, we elected to retain angiography
patients in order to be able to assess risk on a larger patient
population. Baseline serum creatinine was defined as the
Figure 2. Observed vs expected calibration plots. This figure plots the observed vs expected calibration plots for AKI, AKIN 2, CIN, and
dialysis. AKI indicates acute kidney injury; AKIN 2, Acute Kidney Injury Network 2; CIN, contrast-induced nephropathy.
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most recent serum creatinine measurement taken between
365 and 7 days prior to the procedure, a method previously
validated by Siew and colleagues.31 Next, the observed odds
were lower than the predicted odds among the lowest risk of
AKI and therefore the models we derived may slightly
overestimate risk for those whose risk is in the lower tercile
of risk. The prediction model coefficients (and odds ratios)
corresponding to collinear (correlated) groups of variables
should be interpreted cautiously, as they correspond to unit
changes in the variable keeping the correlated variables
constant, which may be unrealistic. Last, because external
validation of the VA models was performed using the
NNECDSG registry, we could only use variables present in
the NNECDSG registry to build our model. The only variables
excluded were those created by the VA EHR from the year
prior to the angiography procedure. Although the inclusion of
these variables in an AKI risk model is one of the innovations
of our study, the external validation of the VA reduced models
proves that the standard variables in registries such as the
NNECDSG, which harmonizes variables with the NCDR data
collection, are generalizable largely to NCDR participating
centers. Therefore, the external validation of the VA AKI risk
models in our investigation is valid and generalizable to non-
VA cardiac catheterization laboratories in the United States.
We must also be mindful about the uncertain implications
of AKI risk modeling for patients and providers. We propose
our preprocedural predictive tool will be used by providers to
assess patients at high risk of AKI and therefore implement
necessary prophylactic strategies to minimize the risk of
AKI.38 Second, providers will need to utilize this tool along
with other tools to determine a safety threshold of contrast
use during the procedure,8,33 and therefore use judgment
regarding duration of case, ad hoc PCI, and number of
interventions. The unintended consequences of identifying
high risk patients for AKI may be delayed or postponed
Table 3. Northern New England Cardiovascular Disease
Study Group External Validation Patient and Disease
Characteristics
No AKI AKI P Value
Procedures (n=27 905) 26 375 1530
Comorbidities
Age 63.7911.93 69.5812.40 <0.001
Female 28.69 38.17 <0.001
Nonwhite race 0.15 0.20 0.667
Tobacco use (any) 27.81 20.39 <0.001
Prior comorbidities
Prior PCI 34.13 31.70 0.051
Prior CABG 16.05 19.74 <0.001
Prior MI 26.96 30.07 0.008
Prior stroke 11.22 20.13 <0.001
Diabetes 30.51 47.12 <0.001




Number of prior comorbid events




Prior renal complications and function
Prior CKD 18.67 43.53 <0.001
eGFR <60, mL/min per
m2
17.77 36.01 <0.001
eGFR <45, mL/min per
m2
0.77 6.01 <0.001




Thrombolytic use 5.04 5.75 0.214
At presentation
Prepresent MI 18.89 25.82 <0.001
Anemia 14.35 23.33 <0.001
Shock 0.79 5.42 <0.001
Unstable angina 0.79 5.42 <0.001
Ejection fraction ≤40% 6.93 15.03 <0.001
Procedural characteristics
Priority
Elective 26.96 11.24 <0.001
Urgent 51.80 53.14 0.31
Emergent 21.20 34.97 <0.001
Salvage 0.03 0.65 <0.001
Continued
Table 3. Continued
No AKI AKI P Value
Ad hoc PCI 83.05 82.36 0.716
Multivessel disease
Number of diseased vessels
Single 58.15 45.56 <0.001
Double 27.21 31.83
Triple 14.64 22.61




AKI indicates acute kidney injury; CABG, coronary artery bypass grafting; CHF,
congestive heart failure; CKD, chronic kidney disease; eGFR, estimated glomerular
filtration rate; MI, myocardial infarction; PCI, percutaneous coronary intervention.
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procedures. Providers will need to balance the tradeoffs of
readiness for cardiac catheterization for patients at high risk
of AKI and potential delays in the procedure with the other
clinical needs and timing of revascularization.
Conclusions
We developed a robust clinical prediction model for AKI
following cardiac catheterization or PCI to be used in a
prospective automated surveillance program in the VA.
These models both explore novel variables that may be
useful in future prediction modeling and risk adjustment,
and we have confirmed external validity in a reduced model
within the NNECDSG registry. This model has been
operationally prioritized by the VA to be incorporated into
routine clinical practice, with the intention to automatically
identify patients at risk of AKI before and immediately
following a cardiac catheterization or PCI procedure. It is
our hope that automated surveillance of AKI will help
clinicians reduce the incidence of AKI and incorporate
protocols to prevent AKI urgently among those patients
identified as high risk.
Table 4. VA Reduced Multivariate Models for External Validation
Risk Factor
Any AKI AKIN 2+ CIN Dialysis
OR (95% CI) OR (95% CI) OR (95% CI) OR (95% CI)
Comorbidities
Age 1.01 (1.01–1.01)* 1.00 (0.99–1.01)
Nonwhite race 1.18 (1.13–1.23)* 1.24 (1.12–1.38)* 1.08 (1.03–1.13)* 1.44 (1.17–1.77)*
Tobacco use (any) 0.89 (0.85–0.92)* 0.95 (0.86–1.05) 1.01 (0.97–1.05) 0.76 (0.61–0.94)*
Prior comorbidities
Prior PCI 0.68 (0.65–0.72)* 0.73 (0.65–0.82)* 0.74 (0.71–0.78)* 0.74 (0.58–0.94)*
Prior CABG 0.80 (0.76–0.86)* 0.84 (0.72–0.99)* 0.82 (0.77–0.88)* 0.69 (0.50–0.97)*
CHF 7 to 365 days 1.45 (1.39–1.51)* 1.75 (1.57–1.94)* 1.37 (1.31–1.43)* 1.51 (1.22–1.87)*
Diabetes 1.05 (1.01–1.09)* 1.43 (1.29–1.58)* 1.22 (1.17–1.27)* 1.37 (1.12–1.68)*
Prior MI 1.05 (0.99–1.12) 0.93 (0.80–1.09) 1.01 (0.95–1.08) 1.04 (0.76–1.42)
Peripheral vascular disease 1.13 (1.08–1.19)* 1.24 (1.11–1.39)* 1.07 (1.02–1.12)* 1.21 (0.97–1.52)
Prior stroke 1.06 (0.99–1.13) 0.86 (0.71–1.04) 1.05 (0.97–1.12) 0.80 (0.55–1.17)
Shock events 0.79 (0.62–1.01) 0.68 (0.43–1.08) 0.68 (0.51–0.91)* 0.67 (0.27–1.68)
Prior renal complications and function
CKD 1.12 (1.05–1.20)* 0.90 (0.78–1.05) 0.79 (0.73–0.85)* 1.54 (1.21–1.97)*
eGFR <60, mL/min per m2 1.57 (1.49–1.66)* 1.73 (1.50–2.01)* 1.31 (1.23–1.39)* 1.57 (1.10–2.25)*
eGFR <45, mL/min per m2 1.49 (1.38–1.60)* 1.52 (1.27–1.81)* 1.41 (1.30–1.53)* 2.54 (1.72–3.76)*
eGFR <30, mL/min per m2 2.44 (2.18–2.73)* 4.54 (3.79–5.44)* 2.81 (2.49–3.16)* 7.43 (5.54–9.96)*
Presentation
Urgent 1.53 (1.47–1.59)* 1.83 (1.64–2.03)* 1.45 (1.39–1.51)* 1.29 (1.04–1.59)*
Emergent 3.24 (3.01–3.48)* 6.21 (5.33–7.23)* 3.34 (3.09–3.61)* 3.35 (2.40–4.67)*
Salvage 5.54 (3.64–8.42)* 13.82 (8.45–22.61)* 4.43 (2.88–6.84)* 2.76 (0.90–8.50)*
Hypertension 0.89 (0.86–0.93)* 0.78 (0.71–0.87)* 0.95 (0.91–0.99)* 0.84 (0.68–1.03)
Unstable angina 0.49 (0.45–0.53)* 0.45 (0.35–0.59)* 0.53 (0.49–0.58)* 0.65 (0.39–1.08)
Ejection fraction ≤40% 1.12 (1.03–1.21)* 0.91 (0.74–1.13) 1.11 (1.02–1.21)* 0.91 (0.60–1.37)
Prepresent MI 1.05 (0.98–1.13) 1.23 (1.03–1.47)* 1.12 (1.04–1.20)* 1.03 (0.72–1.47)
Shock 4.87 (4.23–5.60)* 5.34 (4.43–6.45)* 5.00 (4.31–5.81)* 4.09 (2.83–5.92)*
Anemia 1.62 (1.55–1.68)* 1.68 (1.50–1.88)* 1.65 (1.58–1.72)* 1.41 (1.10–1.81)*
Thrombolytic use 0.71 (0.24–2.14) 1.39 (0.18–10.98) 0.75 (0.25–2.23) 0.00 (0.00–0.00)
AKI indicates acute kidney injury; AKIN, acute kidney injury network; CABG, coronary artery bypass grafting; CHF, congestive heart failure; CIN, contrast-induced nephropathy; CKD, chronic
kidney disease; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; OR, odds ratio; PCI, percutaneous coronary intervention; VA, Veterans Health Administration.
*P<0.05.
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